This is observational study

OTHER2 trials

Sponsors

Korea University Guro Hospital, University College, London

Conditions

Chronic Lung DiseaseCovid-19ImmunogenicityMicrobiomeSARS-CoV-2SarcopeniaVaccine

Unknown Phase

Gut Microbiota, the Potential Key to Modulating Humoral Immunogenicity of New Platform COVID-19 Vaccines

Korea University Guro HospitalCovid-19, Immunogenicity, Microbiome +2

Start: 2021-02-25End: 2023-12-31Target: 53Updated: 2021-12-09

Feasibility of Proteomics in Chronic Lung Disease With Sarcopenia

Not yet recruitingNCT06312774

University College, LondonChronic Lung Disease, Sarcopenia

Start: 2024-04-18End: 2027-01-04Target: 49Updated: 2024-03-15